Satsuma Pharmaceuticals, Inc. STSA NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

Satsuma Pharmaceuticals, Inc. (STSA) — Analyst outlook / Analyst consensus target is. Based on 13 analyst ratings, the consensus is bullish — 4 Buy, 9 Hold.

STSA Analyst Ratings

Hold

Ratings

4 Buy

9 Hold

Based on 13 analysts giving stock ratings to Satsuma Pharmaceuticals, Inc. in the past 3 months

Rating breakdown

Buy

4 31%

Hold

9 69%

31%

Buy

4 analysts

69%

Hold

9 analysts

Sell

0 analysts

People Also View

CytomX Therapeutics, Inc.

$4.56

+0.44%

ASMB

Assembly Biosciences, Inc.

$29.81

+1.26%

FBRX

Forte Biosciences, Inc.

$31.28

-3.52%

LRMR

Larimar Therapeutics, Inc.

$4.83

-0.82%

ELYM

Eliem Therapeutics, Inc.

$5.11

-0.97%

THRX

Theseus Pharmaceuticals, Inc.

$4.07

+0.12%

Satsuma Pharmaceuticals, Inc. STSA NASDAQ

STSA Analyst Ratings

People Also View

Get Undervalued Stock Alerts